1. Home
  2. CNDT vs IKT Comparison

CNDT vs IKT Comparison

Compare CNDT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Conduent Incorporated

CNDT

Conduent Incorporated

HOLD

Current Price

$1.38

Market Cap

232.4M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.74

Market Cap

240.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNDT
IKT
Founded
2016
2008
Country
United States
United States
Employees
51000
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.4M
240.1M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
CNDT
IKT
Price
$1.38
$1.74
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
1.1M
830.6K
Earning Date
05-11-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
$3,042,000,000.00
N/A
Revenue This Year
$2.01
N/A
Revenue Next Year
$4.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$1.33
52 Week High
$2.98
$2.26

Technical Indicators

Market Signals
Indicator
CNDT
IKT
Relative Strength Index (RSI) 35.94 40.45
Support Level $1.33 $1.62
Resistance Level $1.60 $1.74
Average True Range (ATR) 0.12 0.10
MACD -0.05 -0.02
Stochastic Oscillator 10.37 3.66

Price Performance

Historical Comparison
CNDT
IKT

About CNDT Conduent Incorporated

Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: